NITE - Nightstar Therapeutics plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
+0.36 (+2.44%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close14.74
Bid12.50 x 900
Ask999.00 x 800
Day's Range14.51 - 15.50
52 Week Range9.59 - 29.55
Avg. Volume83,295
Market Cap505.61M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.69
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est32.90
Trade prices are not sourced from all markets
  • Mizuho's 9 Best Biotech Stocks to Buy for 2019
    Kiplinger10 days ago

    Mizuho's 9 Best Biotech Stocks to Buy for 2019

    Biotech stocks are a staple among growth investors. The rewards can be staggering - prices on biotechnology shares can literally double overnight - but the risk is just as high. It's not unusual for these stocks to be cut in half or worse if drug-trial data disappoints or a drug application is rejected. Thus, proper due diligence is critical, and that includes tapping the experts for information about these often difficult-to-gauge stocks. Mizuho Securities has recently put out an analyst report highlighting its top biotechnology picks for 2019. And thanks to analyst ranking service TipRanks, we can see that the report's author, Managing Director Difei Yang, has a strong track record of stock recommendations. Yang is ranked in the top 250 out of more than 5,100 tracked analysts. Yang writes, "We favor innovative and ground-breaking therapies in 2019; emerging technologies such as gene therapy and cell therapy could command substantial premiums from large cap pharma/biotech if impressive results are shown in historically difficult-to-treat conditions." As Yang points out, pharma M&A; is off to a strong start in 2019 with a number of blockbuster deals. They include Bristol-Myers Squibb's (BMY) $74 billion acquisition of Celgene (CELG), and Eli Lilly's (LLY) $8 billion buyout of Loxo Oncology (LOXO). "In our view, the transactions underscore the persistent need by large pharma to fuel continued growth and replenish R&D; pipelines via M&A;," she writes. Here are Mizuho's top nine biotech stocks to buy right now. Many of them can stand on their own but look even better as potential buyout targets. ### SEE ALSO: 19 Best Stocks to Buy for 2019 (And 5 to Sell)

  • Is Nightstar Therapeutics plc (NITE) Going to Burn These Hedge Funds?
    Insider Monkey2 months ago

    Is Nightstar Therapeutics plc (NITE) Going to Burn These Hedge Funds?

    During the first half of the fourth quarter the Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by about 4 percentage points as investors worried over the possible ramifications of rising interest rates. The hedge funds and institutional investors we track typically invest more in smaller-cap stocks than an average investor (i.e. […]

  • Benzinga5 months ago

    Wells Fargo Bullish On Applied Genetic Technologies Ahead Of Program Update

    The bullish case for Applied Genetic Technologies Corp (NASDAQ: AGTC ), a nano-cap biotech conducting human clinical trials of adeno-associated virus-based gene therapies, can be made on the basis of an ...

  • Play The Future of Gene Therapy With These 5 Biotech Stocks
    InvestorPlace6 months ago

    Play The Future of Gene Therapy With These 5 Biotech Stocks

    Innovation has always been the mantra when it comes to biotech stocks. Gene therapy is quickly becoming the technique du jour for curing orphan and rare diseases. In a nutshell, gene therapy is fixing those problems by either adding new genes to fight the faulty ones, replacing/editing missing/broken prices or actually “turning off” the genes causing problems.

  • Benzinga6 months ago

    Janney: Nightstar Therapeutics Has 'Significant Upside Potential' With Retinal Disorder Treatments

    Nightstar retains close ties with the University of Oxford, which provides academic expertise as well as strong results from prior studies and the preclinical development of two new programs, Zhong said in the initiation note.

  • 3 Biotech Stocks That Soared This Week: Are They Buys?
    Motley Fool7 months ago

    3 Biotech Stocks That Soared This Week: Are They Buys?

    Can these hot biotech stocks keep the momentum going?

  • Nightstar Therapeutics (NITE) in Focus: Stock Moves 6.3% Higher
    Zacks7 months ago

    Nightstar Therapeutics (NITE) in Focus: Stock Moves 6.3% Higher

    Nightstar Therapeutics (NITE) was a big mover last session, as the company saw its shares rise more than 6% on the day.

  • InvestorPlace9 months ago

    A Focus on Eye Care Is Setting Up Johnson & Johnson Stock for the Future

    While steady growth is appreciated by some investors, that’s not that great overall and doesn’t necessarily support its constant valuation premium. To that end, Johnson & Johnson needs to find some serious growth to keep investors coming back to its shares. Vision care is quickly becoming a major growth engine for JNJ.